Merck & Co., Inc. (MRK) is garnering attention in the biotech market for manifold reasons. Firstly, some analysts believe Merck is one of the best blue chip dividend stocks to buy at present. At the same time,
SG Americas Securities LLC and
Empowered Funds LLC made notable adjustments in their Merck holdings, while others are apprehensive after a 325-point drop in the Dow, worsened by losses in Merck.
Merck has also finalized the acquisition of
EyeBio, although it faced a blow when the FDA surprisingly rejected one of its drugs. This puts the focus on it's Q2 earnings and the robust performance of its cancer 'Star'. An emerging trend is a renaissance in cholesterol treatments that could set a potential $42 billion market, tentatively benefitting Merck.
Shareholders have seen a 91% increase over a three-year period even though there's been a decline in earnings. Merck also surpassed expectations, raising outlook based on strong Keytruda and vaccine sales, which may explain the stock's rally towards a record after FDA gave a green light to its arterial-hypertension drug.
Merck Stocks MRK News Analytics from Tue, 14 Nov 2023 08:00:00 GMT to Sun, 14 Jul 2024 13:59:35 GMT -
Rating 5
- Innovation -3
- Information 8
- Rumor -7
